Related Experiment Videos
Hypertrophic cardiomyopathy in a dog
1Department of Companion Animals, Atlantic Veterinary College, University of Prince Edward Island, Charlottetown, PEI, Canada.
Journal of the American Veterinary Medical Association
|October 1, 1993
Summary
A Corgi with heart failure showed no improvement with standard treatments for congestive cardiomyopathy. Diltiazem administration led to sustained clinical improvement, highlighting its effectiveness in managing hypertrophic cardiomyopathy.
Area of Science:
- Veterinary Cardiology
- Canine Medicine
Background:
- Congestive cardiomyopathy in dogs can be challenging to treat.
- Conventional therapies like furosemide and captopril are standard for heart failure.
Observation:
- A 12-year-old spayed Corgi presented with heart failure unresponsive to conventional therapy.
- Cardiac ultrasonography revealed left ventricular hypertrophy and interventricular septal thickening.
- A diagnosis of primary hypertrophic cardiomyopathy was made due to the absence of a causative agent.
Findings:
- Diltiazem treatment (1.25 mg/kg, PO, q 12 h) resulted in sustained clinical improvement for several weeks.
- This indicates diltiazem's efficacy in managing primary hypertrophic cardiomyopathy in this canine patient.
Implications:
- Complete cardiac evaluation, including echocardiography, is crucial for accurate diagnosis and effective treatment planning in canine heart disease.
- Diltiazem can be a valuable therapeutic option for canine hypertrophic cardiomyopathy when conventional treatments fail.